The mosquito is the world’s deadliest creature, killing 20 times more humans than all other animals combined. There are one billion cases of mosquito disease infections annually,
Little Fly Lab’s technology is a breakthrough in the fight against mosquito-borne diseases.
Leveraging a combination of technology and biology developed by a consortium of global scientific research leaders, LFL’s approach utilizes a proprietary and patent-pending mosquito food source bacterium designed to block vector-borne diseases such as Zika and Dengue Fever.
Throughout history, mosquitoes have brought mankind some of the most widespread and horrific diseases our species has known— Yellow Fever, Malaria, Dengue Fever, West Nile Virus, Encephalitis, Rift Valley Fever, and more.
Today the world faces a new category of mosquito-borne diseases: Zika. And the threat is growing.
Zika — The Unfolding Catastrophe
The Zika virus presents mankind with a new evolutionary enemy requiring immediate and focused attention. It is a frightening and unprecedented disease. There is no cure or vaccine at present, and it will be years before one exists. The most horrific feature of Zika is its attack on human fetal development. It causes microcephaly, severe neurological disorders and countless physical developmental issues.
Little Fly Labs is developing an innovative patent-pending solution to control mosquito-borne diseases by delivering species- and gene-specific double-stranded RNA intended to selectively incapacitate the disease-causing viruses (Zika or Dengue) in each mosquito. This innovation uses naturally occurring microorganisms on which larvae feed to deliver the RNA to the mosquito population.
siRNA—the patented LFL microogranisms—are designed to be gene and organism specific, so there is virtually no chance of off-target hits. They are non-toxic and non-allergenic
After being treated with the LFL microorganism, the mosquito will be incapable of transmitting multiple targeted viruses for its lifetime
EFFECTIVE & SELF-REPLICATING
The solution is fast acting, and the microorganisms replicate over the long term – delivering the disease-fighting genes to future generations of mosquitoes. The platform can also be customized for each virus affect specific regions
The mosquito population is not compromised, ensuring its survival and role in the ecosystem
The approach causes the least possible adverse environmental effects
The control solution is engineered to be easy to disperse and requires fewer applications than other methods
The LFL- solution is designed to be economical to produce and deliver around the world
Our company has harnessed best-in-class leaders of both business and biotechnology science.
+ MICHAEL HARRISON, CHIEF EXECUTIVE OFFICER & CHAIRMAN OF THE BOARD
- 35 years experience in investment banking with interests in the resource, energy and biotech sectors
- Responsible for raising in excess of US$1 billion in funding for private and publicy traded companies
- Served on the Board of Directors for numerous international publicly listed companies
+ DR. FADIA SAAD, PRESIDENT
- 20 years experience in the biotechnology and pharma space, with expertise in bridging science and business
- Previous executive positions in a number of biotechnology companies including Aspreva Pharmaceuticals, MedBiogene and Green Sky Labs
+ JON BLOODWORTH, CHIEF OPERATING OFFICER
- Three decades of senior executive management and legal experience in disruptive technologies, with an emphasis on intellectual property protection and licensing, commercial negotiations, finance and venture development
- Holds a law degree and is an active member of the State Bar of California
+ DR. RICHARD SAYRE, CHIEF SCIENTIFIC OFFICER
- One of the top Research Scientists at Los Alamos National Laboratory and the New Mexico Consortium
- Extensive biotech experience in universities, national laboratories, and the private sector
- One of the top 5 crop scientists who could change the world, according to Nature journal
- Author of over 130 biotechnology papers and patents, with over 7000 citations
- Received over US$100 million in grant funding for various projects
+ KIMBERLY HARRISON, CHIEF DEVELOPMENT OFFICER
- 25 years experience as an entrepreneur across industries
- Experienced in strategy, product development, VC funding, patents, distribution/licensing, and government relations
- Served on numerous international product certifications and standardization committees
+ DR. KONSTANTINOS LYMPEROPOULOS, SCIENTIST
- PhD in Biochemistry from the University of Oxford with a solid scientific background in biochemistry, virology and biophysics
- Expertise in bio-molecular interactions, novel technology platforms and gene therapy
- Author of 11 publications
+ DR. TATIANA VINOGRADOVA-SHAH, SCIENTIST
- PhD in Cell Biology from the Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia
- Expertise in cell and developmental biology
- Author of 11 publications
+ DR. PEDRO MIGUEL MELO DA COSTA NUNES, SCIENTIST
- PhD in Biology from the Instituto Superior de Agronomia, Technical University of Lisbon, Lisbon, Portugal
- Expertise in plant Argonaute diversity and function
- Author of 22 publications
+ SHANNON FLYNN, TECHNICIAN
- 20 years experience in the Department of Energy's environmental science and restoration departments
Board of Directors
+ EDWARD CHEUNG, DIRECTOR
- Over 20 years experience at global investment banks including JPMorgan, Lehman Brothers and Credit Suisse, advising on equities and derivatives to institutions, hedge funds and sovereign wealth funds
- Experience in setting up new businesses including a trading division at a US bank and board member of several startups
+ DAVID SMALLEY, CHIEF COUNSEL
- 17 years practising corporate and securities law, providing legal services for financing private and public companies
- Director of a number of Capital Pool Companies listed for trading on the TSX-Venture Exchange in Canada
- Advises CEOs on their financing and business strategies; provides corporate, commercial and securities legal services
New Mexico Consortium (NMC)
LFL operates within the award winning facilities of the NMC. Chief Technical Officer Dr. Richard Sayre, a Senior Research Scientist at the Los Alamos National Laboratory leads our team of LFL dedicated research scientists and technician.
National Center for Genome Resources USA
A research institute that applies bioinformatics, software engineering and next-generation sequencing to solve the preeminent challenges of 21st century biology through collaborative research and services.
Dr. Callum Bell, President, expertise in transforming advances in genome sequencing into clinical practice.
Colorado State University (CSU)
Arthropod-borne and Infectious Disease Laboratory collaborating with the Department of Defense, and the Centers for Disease Control and Prevention (CDC) - Vector-borne Infectious Diseases.
Dr. Kenneth Olson, Professor of Virology, The Olson Lab.
Dr. Rebekah Kading, Professor of Infectious Disease Annex IDA, The Kading Lab.
Dr. William Black, Professor with expertise on the Aedes aegypti mosquito, The Black Lab.
New Mexico State University (NMSU) - Virus Evolutionary Ecology
Dr. Kathryn Hanley, Professor, co-inventor of the FDA-approved Dengue vaccine, The Hanley Lab.
Dr. John Xu, Associate Professor of Biology, 20 years expertise in the metagenomics of the mosquito ecosystem, The Xu Lab.
60 Minutes: What's being done to fight the Zika virus?
One of the world's most frightening viruses has reached the U.S. Dr. Jon LaPook speaks with the country's top scientists about the fight against Zika.
60 Minutes: Is Zika coming soon to a mosquito near you?
Dr. LaPook explains where Zika is likely to spread in the U.S. and why Americans should worry-- even if they're not pregnant.